The IL-17 pathway is a key component in autoimmune and inflammatory processes, and blocking IL-17 has shown significant success in treating conditions like psoriasis, psoriatic arthritis, and axial spondyloarthritis. In giant cell arteritis (GCA), a large vessel vasculitis affecting individuals over 50, there is growing evidence that IL-17 and Th17 cells play a pathogenic role. GCA is primarily treated with glucocorticoids, but these have significant side effects, especially in older patients. The approval of tocilizumab, an IL-6 receptor antagonist, has provided another treatment option, but there remains a high demand for glucocorticoid-sparing agents. The phase II proof-of-concept study (TiAIN) of secukinumab, an IL-17A inhibitor, showed promising results, with a higher proportion of patients in sustained remission at 28 weeks compared to placebo. The study also demonstrated a longer time to first relapse and no unexpected safety signals. These findings suggest that secukinumab could be a potential new treatment option for GCA, offering a glucocorticoid-sparing approach.The IL-17 pathway is a key component in autoimmune and inflammatory processes, and blocking IL-17 has shown significant success in treating conditions like psoriasis, psoriatic arthritis, and axial spondyloarthritis. In giant cell arteritis (GCA), a large vessel vasculitis affecting individuals over 50, there is growing evidence that IL-17 and Th17 cells play a pathogenic role. GCA is primarily treated with glucocorticoids, but these have significant side effects, especially in older patients. The approval of tocilizumab, an IL-6 receptor antagonist, has provided another treatment option, but there remains a high demand for glucocorticoid-sparing agents. The phase II proof-of-concept study (TiAIN) of secukinumab, an IL-17A inhibitor, showed promising results, with a higher proportion of patients in sustained remission at 28 weeks compared to placebo. The study also demonstrated a longer time to first relapse and no unexpected safety signals. These findings suggest that secukinumab could be a potential new treatment option for GCA, offering a glucocorticoid-sparing approach.